We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking "Accept," you agree to our website's cookie use as described in our Privacy Policy.
ACCEPTDenyPREFERENCES
+

Link to Healthcare Professionals Site

The information contained in this section is intended for U.S. healthcare professionals only.

Enter the SiteCancel
+

Link to Healthcare Professionals Site

The information contained in this section is intended for U.S. healthcare professionals only.

Enter the SiteCancel
+

Find a Prescriber Near You

* Intended for US residents only
Thank you!

We will contact you promptly.
Oops! Something went wrong while submitting the form.

Scientific literature related to Luminopia, Inc.

Location
Author - Title
Date
AAPOS 2025
N Warner et al - Initial Outcomes in Older Children on Dual-Mechanism Binocular Treatment for Amblyopia: PUPiL Registry Results
March 2025
View
AAPOS 2025
B Bohnsack et al - Durability of Real World Vision Gains Following Completion of Dual-Mechanism Binocular Treatment: PUPiL Registry Results
March 2025
View
Journal Ophthalmology
I Koc et al - Cost-effectiveness Analysis of Digital Therapeutics for Amblyopia
January 2025
View
American Academy of Optometry 2024
E Horn et al - Patient Usage Behaviors and Visual Acuity Outcomes with a Digital, Dual-Mechanism Treatment for Amblyopia
November 2024
View
American Academy of Optometry 2024
E Bennet et al - Real World Results of Dual-Mechanism Digital Amblyopia Treatment in Patients Previously Treated for Amblyopia: Results of the PUPiL Registry
November 2024
View
American Academy of Optometry 2024
M Bodack et al - Real World Amblyopia Patient Outcomes following DIgital Dual-Mechanism Treatment: Initial Outcomes from the PUPiL Registry
November 2024
View
American Academy of Optometry 2024
C Lai et al - Compliance & VIsion Outcomes Following Dual-Mechanism Digital Treatment of Amblyopia by Coverage: PUPiL Registry Real World Results
November 2024
View
AMCP Nexus 2024
N Warner et al - Real World Vision and Health Equity Outcomes With a Dual-Mechanism Digital Treatment for Amblyopia: Results from the PUPiL Registry
October 2024
View
AAO 2024
Real-World Registry Outcomes of an FDA-Approved Binocular Therapy for Amblyopia
October 2024
View
AACO 2024
D Hunter - Real-World Amblyopia Patient Outcomes following Luminopia Treatment
October 2024
View
ESA-ISA 2024
D Sprunger et al - A Patient Registry for the Binocular, Dual-Acting Digital Therapeutic for Amblyopia from Anisometropia & Mild Strabismus: Real-World Outcomes following Prescription of Luminopia
June 2024
View
ARVO 2024
F Ghasia et al - Outcomes for Binocular, Dual-Acting Therapy for Amblyopia in the Real World: The First Three Months in Previously Treated Patients
May 2024
View
ARVO 2024
B Bohnsack et al - Real World Study of an FDA-Approved Binocular, Dual-Acting Therapy for Amblyopia: Initial Outcomes from Treatment Registry
May 2024
View
AMCP 2024
S Hancock et al - Real World Study of an FDA-Approved Binocular, Dual-Acting Therapy for Amblyopia: Vision and Compliance Outcomes from the Treatment Registry
April 2024
View
AAPOS 2024
E Koo et al - Real World Study of an FDA-Approved Binocular, Dual-Acting Therapy for Amblyopia: Initial Outcomes from the Treatment Registry
April 2024
View
AAPOS 2024
I Oke et al - Digital Therapeutic User Behaviors Associated with Amblyopia Recovery
April 2024
View
SECO 2024
E Bennett et al - Luminopia from Clinical Trial to Real World Outcomes
February 2024
View
American Academy of Ophthalmology
AAO - Amblyopia Preferred Practice Pattern
Updated February 2024
View
Journal of AAPOS
I Oke et al - Factors associated with visual acuity improvement with a binocular digital therapeutic for amblyopia
February 2023
View
Ophthalmology
Xiao et al - Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia
September 2021
View
Journal of AAPOS
S Xiao et al - Digital therapeutic improves visual acuity and encourages high adherence in amblyopic children in open-label pilot study
April 2021
View
Scientific Reports
Xiao et al - Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia
May 2020
View
Luminopia is FDA-approved (via the de novo process).

Indication: Luminopia is indicated for improvement in visual acuity in amblyopia patients age 4-7, associated with anisometropia and/or with mild strabismus. Luminopia is for Prescription Use Only.

Please see the Luminopia Directions for Use for more information.